




The relative strengths and weaknesses of Cytomx Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cytomx Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 30% points. The greatest weakness of Cytomx Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 153% points.

The company's Economic Capital Ratio, given in the ranking table, is 170%, being 82% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	388,601
Cost of Goods Sold	0
Intangible Assets	949
Liabilities, Current	61,147
Liabilities, Non-Current	1,897
Other Assets	3,876
Other Compr. Net Income	-67
Other Expenses	-513
Other Liabilities	264,704
Other Net Income	2,647
Other Revenues	71,623
Property and Equipment	4,218
Research and Development	92,277
Selling, General and Administrative Expense	25,605

Output Variable	Value in 1000 USD
Assets	397,644
Liabilities	327,748
Expenses	117,369
Revenues	71,623
Stockholders Equity	69,896
Net Income	-43,099
Comprehensive Net Income	-43,132
BaseVar	458,549
ECR before Limited Liability	30%
Economic Capital Ratio	170%